Vincerx Pharma Inc
NASDAQ:VINC
Income Statement
Earnings Waterfall
Vincerx Pharma Inc
Income Statement
Vincerx Pharma Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||
| Operating Expenses |
(11)
|
(20)
|
(38)
|
(55)
|
(63)
|
(75)
|
(76)
|
(73)
|
(69)
|
(65)
|
(57)
|
(50)
|
(43)
|
(35)
|
(30)
|
(28)
|
(31)
|
|
| Selling, General & Administrative |
(4)
|
(5)
|
(11)
|
(17)
|
(23)
|
(23)
|
(21)
|
(20)
|
(19)
|
(18)
|
(17)
|
(16)
|
(14)
|
(12)
|
(12)
|
(12)
|
(16)
|
|
| Research & Development |
(7)
|
(5)
|
(16)
|
(28)
|
(40)
|
(51)
|
(54)
|
(53)
|
(50)
|
(45)
|
(39)
|
(34)
|
(29)
|
(23)
|
(18)
|
(16)
|
(15)
|
|
| Other Operating Expenses |
0
|
(11)
|
(11)
|
(10)
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(11)
N/A
|
(20)
-89%
|
(38)
-85%
|
(55)
-47%
|
(63)
-14%
|
(75)
-19%
|
(76)
-1%
|
(73)
+3%
|
(69)
+6%
|
(65)
+5%
|
(57)
+12%
|
(50)
+13%
|
(43)
+15%
|
(35)
+19%
|
(30)
+14%
|
(28)
+6%
|
(31)
-12%
|
|
| Pre-Tax Income | ||||||||||||||||||
| Interest Income Expense |
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(2)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(5)
|
(3)
|
13
|
6
|
23
|
25
|
11
|
17
|
8
|
3
|
2
|
2
|
1
|
(4)
|
1
|
1
|
1
|
|
| Pre-Tax Income |
(17)
N/A
|
(23)
-38%
|
(25)
-8%
|
(49)
-97%
|
(39)
+20%
|
(49)
-26%
|
(66)
-33%
|
(58)
+12%
|
(63)
-8%
|
(61)
+3%
|
(54)
+11%
|
(46)
+14%
|
(40)
+14%
|
(38)
+6%
|
(28)
+26%
|
(27)
+4%
|
(30)
-11%
|
|
| Net Income | ||||||||||||||||||
| Income from Continuing Operations |
(17)
|
(23)
|
(25)
|
(49)
|
(39)
|
(49)
|
(66)
|
(58)
|
(63)
|
(61)
|
(54)
|
(46)
|
(40)
|
(38)
|
(28)
|
(27)
|
(30)
|
|
| Net Income (Common) |
(17)
N/A
|
(23)
-38%
|
(25)
-8%
|
(49)
-97%
|
(39)
+20%
|
(49)
-26%
|
(66)
-33%
|
(58)
+12%
|
(63)
-8%
|
(61)
+3%
|
(54)
+11%
|
(46)
+14%
|
(40)
+14%
|
(38)
+6%
|
(28)
+26%
|
(27)
+4%
|
(30)
-11%
|
|
| EPS (Diluted) |
-63.29
N/A
|
-33.32
+47%
|
-30.34
+9%
|
-55.27
-82%
|
-45.77
+17%
|
-47.33
-3%
|
-62.72
-33%
|
-55.2
+12%
|
-59.9
-9%
|
-57.77
+4%
|
-51.08
+12%
|
-43.53
+15%
|
-37.71
+13%
|
-35.45
+6%
|
-14.7
+59%
|
-11.83
+20%
|
-15.85
-34%
|
|